ESR1 and breast neoplasm: The presence of the estrogen receptor (ER) on breast tumours has been shown to be a good biomarker to identify those patients who respond to anti-estrogenic therapy such as tamoxifen or lowering of circulating estrogen levels with aromatase inhibitors (e.g., anastrozole, letrozole or exemestane).